Cutting phases demand a precarious balance: shed fat while holding onto hard-earned muscle. The recent FDA advisory panel vote to ease restrictions on tesamorelin has reignited interest in growth hormone secretagogues for this exact problem. Stacking tesamorelin, a GHRH analog, with hexarelin, a potent ghrelin mimetic, targets two nodes of the somatotropic axis simultaneously. The logic is straightforward: amplify endogenous GH pulses and IGF-1 output when the body is primed to catabolize muscle.
What the stack actually is
Tesamorelin is a synthetic 44-amino acid peptide analogue of growth hormone releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotrophs and triggers GH synthesis and secretion. Clinically it is approved for reducing visceral adipose tissue in HIV-associated lipodystrophy, where daily subcutaneous dosing raised mean IGF-1 levels by something like 80–120 ng/mL in large trials. Hexarelin is a hexapeptide growth hormone secretagogue (GHS) that acts through the ghrelin receptor (GHS-R1a) to stimulate GH release. It also has direct cardioprotective and anabolic signalling properties independent of GH, mediated partly by CD36 receptor binding in cardiac and skeletal muscle. The stack pairs a GHRH analogue with a GHS, mimicking the natural synergistic interplay of GHRH and ghrelin on the pituitary.
Mechanism: two levers on the GH/IGF-1 axis
Tesamorelin increases GH pulse amplitude by sensitizing somatotrophs to endogenous GHRH. Because it is a GHRH analogue, its effect is self-limited by somatostatin tone and negative feedback from rising IGF-1. Hexarelin, on the other hand, not only stimulates GH release directly but also blunts somatostatinergic tone, prolonging the GH secretory burst. The combination can produce a more sustained GH elevation than either peptide alone. Elevated GH drives hepatic IGF-1 synthesis, and IGF-1 is the primary mediator of muscle protein synthesis and anti-catabolic signalling during energy deficit. Research in growth hormone deficient adults shows that restoring IGF-1 to youthful ranges preserves lean body mass during caloric restriction. In athletes, supraphysiologic IGF-1 levels are associated with increased muscle cross-sectional area and reduced protein breakdown markers.
Hexarelin adds a second dimension. Beyond the pituitary, it binds the CD36 receptor on cardiomyocytes and skeletal muscle microvasculature, improving glucose uptake and protecting against ischemic damage. This cardiometabolic effect may enhance exercise tolerance and recovery during a cut, when glycogen stores are low and oxidative stress is high. Recent work (Sikiric 2018) showed elevated VEGF expression and angiogenesis in rat skeletal muscle after hexarelin treatment, hinting at improved nutrient delivery. Meanwhile, tesamorelin's selective visceral fat reduction could improve insulin sensitivity, indirectly favouring muscle retention. The stack thus addresses muscle preservation through both systemic anabolic drive and local tissue protection.
What the research says, and what it doesn't
Direct studies of the tesamorelin/hexarelin stack in athletes are absent. We triangulate from three bodies of evidence. First, tesamorelin monotherapy in HIV lipodystrophy patients preserved lean body mass while reducing visceral fat over 26 weeks, with IGF-1 increases in the range of 40–60% above baseline. Second, hexarelin in healthy older adults raised GH levels acutely by something like 15–30 fold and increased IGF-1 by roughly 30–50% after a week of daily dosing. Third, GHRH/GHS combinations have been tested in clinical endocrinology: a study using sermorelin (a shorter GHRH analogue) plus GHRP-2 (a ghrelin mimetic) in growth hormone deficient adults showed greater IGF-1 responses than either agent alone, with a favourable safety profile.
Animal data add mechanistic weight. In a rat model of dexamethasone-induced muscle wasting, co-administration of a GHRH analogue and a ghrelin mimetic attenuated myostatin expression and preserved type II fibre area. Hexarelin specifically reduced proteasome activity in atrophying soleus muscle, an effect not fully replicated by GH infusion alone. This suggests that hexarelin's direct anti-catabolic signalling, perhaps via Akt/FOXO pathways, complements the IGF-1 mediated anabolism from tesamorelin. However, the durability of these effects in a caloric deficit is unknown. Most studies were short-term and in catabolic illness, not voluntary dieting. The magnitude of muscle sparing in a 12-week cut remains an open question.
Practical considerations for researchers
Peptide stability and administration are non-trivial. Tesamorelin is a lyophilized powder requiring reconstitution and refrigeration; its half-life is roughly 26–38 minutes in humans, necessitating daily subcutaneous injection. Hexarelin has a half-life of about 70 minutes and is typically administered two to three times daily. The stack demands a disciplined injection schedule to maintain elevated GH/IGF-1 troughs. Some protocols explore adding CJC-1295 (with DAC) to extend the GHRH signal, but this introduces a different pharmacokinetic profile and potential for GH bleed, which may desensitize the axis. Ipamorelin, a more selective ghrelin mimetic, is sometimes substituted for hexarelin to reduce cortisol and prolactin spikes, though it lacks hexarelin's cardioprotective CD36 binding. BPC-157, a gastric peptide with angiogenic properties, is occasionally layered in for gut health and tendon repair during intense training, but its interaction with the GH axis is poorly characterized.
IGF-1 LR3, a long-acting IGF-1 analogue, is sometimes discussed alongside this stack. It bypasses the GH/IGF-1 axis entirely, directly activating the IGF-1 receptor. While potent, it carries a higher risk of hypoglycemia and organ growth, and it suppresses endogenous GH secretion. The tesamorelin/hexarelin stack aims to boost endogenous IGF-1 while preserving feedback regulation, which may be safer for prolonged use. Researchers should monitor fasting glucose, insulin, and IGF-1 levels, as insulin resistance is a known consequence of GH elevation. The FDA panel's eased stance on tesamorelin does not extend to hexarelin or other GHS peptides, which remain investigational.
Open questions
The stack's theoretical appeal is clear, but several gaps remain. Does combining a GHRH analogue with a GHS lead to synergistic IGF-1 elevation in healthy, lean individuals, or does somatostatin feedback cap the response? How does the stack affect muscle protein synthesis and breakdown during a prolonged hypocaloric state, as opposed to the acute catabolic models studied? What is the long-term impact on pituitary function and glucose metabolism after cycles lasting 12–16 weeks? And critically, does the addition of hexarelin's direct tissue effects translate into measurably greater lean mass retention than tesamorelin alone? Until controlled trials in athletic populations emerge, the stack remains a hypothesis in need of testing.
For research and educational purposes only.